Best Peptides for Longevity: Research-Ranked and Cited

What makes a peptide a "longevity" peptide?

A longevity peptide is one studied against a recognized driver of biological aging, not just a cosmetic or performance goal.

Researchers describe several hallmarks of aging, including telomere shortening, mitochondrial dysfunction, loss of protein and gene-expression balance, and declining hormone signaling. A peptide earns a place in the longevity conversation when studies tie it to one of those pathways with real data. That is a lower bar than "makes people live longer." It means the molecule acts on a mechanism that aging researchers care about. Whether that mechanism translates into a longer or healthier human life is a separate, mostly unanswered question. The compounds below are ranked by how solid and how relevant their published evidence is, with the human-versus-animal gap stated plainly for each.

Which are the best peptides for longevity by weight of evidence?

The short answer: MOTS-c and SS-31 have the clearest mechanistic and animal data on mitochondrial aging, GHK-Cu has the most striking gene-expression data, humanin has direct lifespan data in simple organisms, and epithalon has the boldest telomere claims but the weakest independent human evidence. None has proven human lifespan extension.

The ranking that follows walks these in order of how much weight the evidence can bear.

How strong is the evidence for MOTS-c?

MOTS-c is a mitochondrial-derived peptide that acts as a metabolic signal, mainly by switching on the energy sensor AMPK.

MOTS-c is a 16 amino acid peptide encoded inside the mitochondrial genome, which is unusual, since almost all signaling peptides are encoded in the cell nucleus (Lee et al., Cell Metabolism 2015;21(3):443-454, PMID 25738459). The founding study reported that MOTS-c activated AMPK, improved insulin sensitivity, and limited high-fat-diet-induced weight gain and insulin resistance in mice. AMPK is the same fuel sensor that exercise and metformin are known to trigger, which is why MOTS-c is framed as a link between mitochondria and whole-body metabolism.

The exercise angle strengthens its longevity case. A 2021 study reported that a single bout of cycling raised MOTS-c about 11.9-fold in human muscle and about 1.6-fold in blood, and that injecting MOTS-c was associated with improved running capacity in young, middle-aged, and old mice, including late-life dosing (Reynolds et al., Nature Communications 2021;12:470, doi:10.1038/s41467-020-20790-0). The catch is the same one that follows every peptide here: the treatment effects were measured in mice, while the human part was an observation that exercise raises the peptide. Human MOTS-c levels also fall with age and track worse metabolic health, but that is a correlation, not proof (Kong, Lee, and Cho, Diabetes Metab J 2023;47(3):315-324, doi:10.4093/dmj.2022.0333). See the full breakdown at /mots-c.

What does the research show on SS-31 (elamipretide)?

SS-31, also known as elamipretide, works by binding a lipid called cardiolipin in the inner mitochondrial membrane, which helps the cell's energy machinery run cleaner.

This is the compound on the list furthest along a regulatory path, though not for aging. Elamipretide (from Stealth BioTherapeutics) has been studied in people with Barth syndrome, a rare inherited mitochondrial disorder, and is under FDA review; treat any longevity use as investigational. Its mechanism is why longevity researchers watch it: by stabilizing cardiolipin and the respiratory chain, it supports mitochondrial energy output and lowers reactive oxygen species. That matters because mitochondrial decline is a recognized hallmark of aging.

The aging-specific data are from animals. A 2019 study reported that eight weeks of SS-31 in aged mice was associated with improved treadmill endurance, higher mitochondrial ATP production, and better redox balance in skeletal muscle (Campbell et al., Free Radical Biology and Medicine 2019, PMID 30597195). That is a healthspan signal, but it is in mice, and the human work is for a specific rare disease, not for slowing aging in healthy adults. Treat the longevity use as investigational. See the full breakdown at /ss-31.

What is the evidence for GHK-Cu and longevity?

GHK-Cu is a copper-bound tripeptide that research links to broad shifts in gene expression, including genes for tissue repair and DNA repair.

GHK-Cu is the small human peptide glycyl-L-histidyl-L-lysine bound to a copper ion, first isolated from human plasma in the 1970s. Its levels in blood decline with age. The finding that put it on the longevity map: an analysis reported that GHK-Cu changed the expression of about 31% of human genes at a 50% or greater threshold, with those changes mapping to tissue repair, antioxidant defense, inflammation control, and DNA repair (Pickart & Margolina, International Journal of Molecular Sciences 2018;19(7):1987, PMID 29986520). Older work established the concrete piece under that: GHK-Cu stimulates collagen synthesis in human skin fibroblasts at very low concentrations (Maquart et al., FEBS Letters 1988;238(2):343-346, PMID 3169264).

Here is the honest boundary. The gene-expression data are largely from cell-culture and bioinformatic analysis, and the strongest human evidence is for topical use on skin, not for injected anti-aging or lifespan. A wide gene-expression footprint is intriguing but is not the same as a proven aging effect in people. GHK-Cu belongs on this list for its mechanism and its skin data, and its main documented human role is dermatological. Full detail at /ghk-cu, and the class overview at /copper-peptides.

Does humanin have real lifespan data?

Humanin is a mitochondrial-derived peptide that research links to cell protection and, in simple organisms, to a longer lifespan.

Humanin was the first mitochondrial-derived peptide discovered, a 24 amino acid peptide encoded in mitochondrial DNA. It is described as cytoprotective, blocking certain cell-death signals and supporting cells under metabolic and neurological stress. The most direct longevity finding: a 2020 study reported that humanin overexpression was associated with a longer lifespan in the worm C. elegans through the insulin/IGF signaling pathway, that a humanin analog improved metabolic markers in mice, and that circulating humanin declines with age in most species (Yen K, Mehta HH, Kim SJ, et al., Aging 2020;12(12):11185-11199, doi:10.18632/aging.103534).

The most quoted human data point is an association: children of centenarians carried significantly higher humanin levels than age-matched controls (Yen et al., Aging 2020). That is a correlation with human longevity, not evidence that giving humanin extends a person's life. The lifespan effect itself was observed in a worm, and the direct treatment data are in animals. Humanin is a research compound with no approved human use. It sits alongside MOTS-c in the mitochondrial-derived peptide cluster; see /mots-c for its better-studied sibling.

Are GH-axis peptides (CJC-1295, tesamorelin) longevity peptides?

GHRH-analog peptides such as CJC-1295 and tesamorelin push the pituitary to release more of its own growth hormone, which naturally falls with age.

The logic is replacement, not extension. Growth hormone and IGF-1 decline steadily with age, and GHRH analogs are studied as a way to nudge that axis back up. CJC-1295, a long-acting GHRH analog, raised mean GH about 2 to 10 fold and IGF-1 about 1.5 to 3 fold after a single dose in healthy adults (Teichman et al., Journal of Clinical Endocrinology and Metabolism 2006;91(3):799-805). Tesamorelin, an approved GHRH analog, reduced visceral fat by about 15.2% versus a rise on placebo in its trial population (Falutz et al., NEJM 2007;357:2359-2370, doi:10.1056/NEJMoa072375).

Two cautions keep this in perspective. First, raising GH and IGF-1 is a body-composition and hormone effect, not a demonstrated way to live longer. In fact, some aging research points the other way, associating lower IGF-1 signaling with longer life in several models, so more GH is not a clean longevity bet. Second, the approved uses are specific, and using these to chase anti-aging is off-label and investigational. See /cjc-1295-ipamorelin-dosage, /cjc-1295-ipamorelin-side-effects, /tesamorelin, and /sermorelin for the GH-axis family in depth.

How credible are the epithalon telomere claims?

Epithalon is a four amino acid pineal-derived peptide claimed to activate telomerase and lengthen telomeres, but its human evidence comes almost entirely from a single research group.

Epithalon (sequence Ala-Glu-Asp-Gly) draws attention because telomere shortening is a hallmark of aging and epithalon is reported to touch it directly. A 2003 cell study reported that epithalon induced telomerase activity and telomere elongation in human somatic cells in culture (Khavinson, Bondarev, and Butyugov, Bulletin of Experimental Biology and Medicine 2003;135(6):590-592, PMID 12937682). Small human studies from the same lab reported lower mortality and better aging markers in older adults given a related pineal peptide over multi-year follow-up (Korkushko, Khavinson, Shatilo, and Antonyk-Sheglova, Bulletin of Experimental Biology and Medicine 2011;151(3):366-369, PMID 22451889), though these trials were small and mostly single-group.

The reason epithalon ranks low despite the boldest claims is candor about the evidence. Most of the research originates from one institute and has limited independent replication. And the animal lifespan data are mixed, not uniformly positive: one study in mice reported that epithalon was associated with slower age-related changes and less chromosome damage but did not increase mean lifespan (Anisimov et al., Biogerontology 2003). Human data are limited, largely single-source, and there is no regulatory approval. Epithalon is worth knowing as the telomere-focused option, but the gap between the online claims and the verifiable evidence is the widest on this page. See /epithalon.

Where do NAD-adjacent compounds fit?

NAD+ is not a peptide, so it sits outside this ranking, but it is the metabolic backdrop many longevity peptides act against.

You will see NAD+ mentioned in almost every longevity discussion. NAD+ (nicotinamide adenine dinucleotide) is a molecule central to energy metabolism, and reviews report that it declines in the tissues of aged animals, with the human evidence still limited (McReynolds, Chellappa, and Baur, Experimental Gerontology 2020;134:110888, PMID 32097708). NAD+ boosters like NMN and NR are small molecules, not peptides, so they are out of scope for a peptide hub. The connection worth holding: MOTS-c and SS-31 both act on mitochondrial function, the same system NAD+ supports, which is why these threads get braided together. If you came here for NAD+ precursors specifically, this is a peptide page, and those compounds are a different category.

Which longevity peptide suits which goal?

There is no "best" here in an outcome sense, because none has proven a longevity outcome in people. But the mechanisms suit different research interests.

If the interest is mitochondrial and metabolic aging, MOTS-c and SS-31 have the most coherent mechanism-to-animal story, and SS-31 is the only one that has advanced to human trials (for a rare disease). If the interest is tissue repair and skin aging, GHK-Cu has the deepest gene-expression and dermatological data. If the interest is the growth-hormone decline of aging, the GHRH analogs are the studied lever, with the caveat that more GH is not clearly pro-longevity. If the interest is telomeres, epithalon is the named option, held against the weakest independent evidence. And humanin is the compound to watch in the mitochondrial-derived peptide space, with real lifespan data in worms but only associations in humans. For adjacent goals, see /peptides-for-recovery and /peptides-for-muscle-growth, and start with /what-are-peptides if you are new to the category.

What does the research report on dosing for longevity peptides?

The ranges below reflect what published studies and commonly studied research protocols report. This is educational, not a prescription or a personal recommendation.

Two facts frame this table. First, most of these figures come from animal studies in milligrams per kilogram, which does not convert to a fixed human dose, since body-size scaling between species is not simple multiplication. Second, there is no established human longevity dose for any peptide here, because none has completed human trials for a longevity endpoint. The table shows what specific studies actually used, with the source for each.

A note on unit math, shown generically as a reference and not as an instruction to dose: a milligram amount only maps to an insulin-syringe "unit" reading after the compound is dissolved in a known volume of liquid. As a generic example, if 10 mg of any peptide is dissolved in 1 mL of liquid, that is 10 mg per mL, and a U-100 insulin syringe reads 100 units per mL, so 1 mg would correspond to 10 units on that scale. That is arithmetic for reading a label, not guidance to dose. For the mechanics of preparing a vial, see /reconstitution, and for verifying what is actually in a vial, see /coa.

Are longevity peptides safe?

Human safety data are thin for most of these, because they are research compounds rather than approved medicines, so a candid answer is that long-term safety in people is largely unknown.

Only tesamorelin has completed the kind of human safety testing approved drugs go through, and elamipretide has advanced through human trials for a rare disease, but neither is approved for anti-aging use in healthy adults. For MOTS-c, humanin, GHK-Cu as an injectable, and epithalon, there is no large human safety database, so the honest position is that their side-effect profiles over months and years are not well characterized. Two points apply to any injectable research compound: injection-site reactions like redness or soreness are possible, and because effects and risks depend on what is truly in the vial, purity matters, which is why a certificate of analysis is worth reviewing. For the general safety picture see /are-peptides-safe and /peptide-side-effects.